Acerus Pharmaceuticals Corporation  

(Public, CVE:JV.P)   Watch this stock  
Find more results for Gregory P. Hawkins�
Feb 4 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.21
Open     -
Vol / Avg. 0.00/19,467.00
Mkt cap 1.20M
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 40.25% -525.04%
Operating margin -13.07% -502.34%
EBITD margin - -407.84%
Return on average assets 6.98% -43.52%
Return on average equity 50.47% -150.79%
Employees 19 -
CDP Score - -


2486 Dunwin Drive
+1-416-6790771 (Phone)


Acerus Pharmaceuticals Corp, formerly Trimel Pharmaceuticals Corp, is a pharmaceutical company that focuses on the development, manufacture, marketing and distribution of products with a focus in men's health and women's health. The Company's products include Natesto, which is nasal testosterone replacement therapy that is developed for the treatment of male hypogonadism (Low T); Estrace, which is an oral 17-beta estradiol tablet used for the symptomatic relief of menopausal symptoms, and Tefina, which is a low-dose nasal testosterone gel that is developed for the treatment of female orgasmic disorder. The Company's Tefina product has completed its Phase II clinical trial. The Company holds a license for the development and marketing rights of its products utilizing a bio adhesive intranasal gel drug delivery technology platform, and owns a unit-dose dry powder inhaler/nasal dispersion system, TriVair.

Officers and directors

Ian O. Ihnatowycz Independent Chairman of the Board
Age: 61
Tom Rossi President, Chief Executive Officer, Director
Michael Bumby Chief Financial Officer
Age: 50
Matthew Hawkins Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson Vice President - Scientific Affairs
Rolf K. Reininghaus Executive Director, Director
Stephen Robert Gregory Lead Independent Director
Norma Beauchamp Director
Borys Chabursky Director
Josef Vejvoda Director
Age: 50